Get the Stockscreener App
2.90
5.54%
-0.17
After Hours:
2.95
0.05
+1.72%
Prime Medicine Inc stock is traded at $2.90, with a volume of 7.08M.
It is down -5.54% in the last 24 hours and down -21.83% over the past month.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
See More
Previous Close:
$3.07
Open:
$3.42
24h Volume:
7.08M
Relative Volume:
2.13
Market Cap:
$525.99M
Revenue:
$4.03M
Net Income/Loss:
$-198.37M
P/E Ratio:
-2.3108
EPS:
-1.255
Net Cash Flow:
$-158.74M
1W Performance:
-7.05%
1M Performance:
-21.83%
6M Performance:
-20.11%
1Y Performance:
-44.44%
1-Day Range:
$2.875
$3.44
1-Week Range:
$2.875
$3.565
52-Week Range:
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
2.90 | 525.99M | 4.03M | -198.37M | -158.74M | -1.255 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Oppenheimer | Outperform |
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
PRME Stock Dips As Prime Medicine Faces Steep Losses - StocksToTrade
Prime Medicine Stock Slips As Traders Digest Weak Margins - StocksToTrade
Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME) - Seeking Alpha
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Gets FDA Green Light for Gene Editing Study - Benzinga
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says - marketscreener.com
Prime Medicine (NASDAQ:PRME) Shares Gap UpWhat's Next? - MarketBeat
FDA Clears Prime Medicine to Start Gene Editing Trial After Beam Dispute - GenomeWeb
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine’s PM-647 gains IND approval for AATD - BioWorld News
Prime Medicine (NASDAQ:PRME) Stock Keeps Buy Rating at Chardan Capital - MarketBeat
Prime Medicine stock holds at outperform on FDA IND clearance By Investing.com - Investing.com Australia
Prime Medicine stock holds at outperform on FDA IND clearance - Investing.com
Prime Medicine stock jumps 8% after FDA clears PM647 trial - TradingView
Chardan Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Stocks to Watch: Akamai, Scholastic, Prime Medicine - Moomoo
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency - TradingView
Why is Prime Medicine stock surging today? By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Prime Medicine stock surges on FDA IND clearance - finance.yahoo.com
Prime Medicine receives FDA clearance for AATD gene therapy - Investing.com
FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. - Stock Titan
Prime Medicine (PRME) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.5%Should You Sell? - MarketBeat
Can Prime Medicine (NASDAQ:PRME) Afford To Invest In Growth? - Moomoo
Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine (NASDAQ:PRME): What's Behind Its Sudden Share Price Jump? - Kalkine Media
Prime Medicine (NASDAQ:PRME) Shares Up 11.8%Should You Buy? - MarketBeat
PRME: Prime Editing advances versatile gene therapies with strong clinical and financial momentum - TradingView
Prime Medicine at H.C. Wainwright conference: platform gains focus By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.3%Here's What Happened - MarketBeat
A gene-editing company sets three September conference appearances - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - marketbeat.com
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 6.3%Here's What Happened - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.9%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
Prime Medicine Company Profile & Introduction - Moomoo
PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget
PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the DayConsensus Beat Rate - vinanet.vn
BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada
Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime (PRME) Earnings Recap: EPS Beats Its Estimate; Trading-Day Reaction: Shares Finish 3.47% Down in the Current UpdateRetail Earnings Report - careplusvn.com
Prime Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):